Bispecific antibody therapeutic - Lava Therapeutics
Latest Information Update: 18 Sep 2020
At a glance
- Originator Lava Therapeutics
- Developer Amsterdam UMC; Lava Therapeutics; Monash University
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Natural killer cell stimulants; Natural killer T cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Acute myeloid leukaemia; Multiple myeloma